Modality
Gene Therapy
MOA
Menini
Target
VEGF
Pathway
PD-1/PD-L1
GISTADHD
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
~Oct 2022
→ ~Jan 2024
Phase 2
Apr 2024
→ Jan 2027
Phase 2Current
NCT06140542
2,682 pts·GIST
2024-04→2027-01·Recruiting
2,682 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2110mo awayPh3 Readout· GIST
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-01-21 · 10mo away
GIST
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06140542 | Phase 2/3 | GIST | Recruiting | 2682 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |